EUVIMEDEUVIMED entdecken
Crossref

Linking Baseline PSMA PETDerived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [ 177 Lu]Lu-PSMA-617: A Single-Center Retrospective Study

Vishnu Murthy, Koichiro Kimura, Lela Theus, Andrew Nguyen, Tristan R Grogan, Ojaswita Lokre, Timothy Perk, Matthew B Rettig, Alexandra Drakaki, John Shen, Pan Thin, Kathleen Nguyen und 7 weitere

Journal of Nuclear Medicine · 2026-02 · 67 (2) · 246-252

DOI: 10.2967/jnumed.125.270916 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 04.12.2025. Verfasst von Vishnu Murthy und 18 weiteren Autor:innen. Beteiligte Einrichtung: Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles,…. Hauptthemen laut MEDLINE: Dipeptides, Heterocyclic Compounds, 1-Ring, Lutetium, Quality of Life. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to investigate whether quantitative parameters derived from baseline prostate-specific membrane antigen (PSMA) PET imaging can predict hematologic toxicity and patient-reported outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with 177Lu-PSMA-617.

Methods

This retrospective study analyzed data from the U.S. expanded-access program at UCLA (NCT04825652). We included 61 patients with mCRPC who received 177Lu-PSMA-617 between May 2021 and March 2022 and had available baseline PSMA PET scans, hematologic toxicity data, and patient-reported outcomes. Questionnaires included the Functional Assessment of Cancer Therapy-Prostate (FACT-P), the Brief Pain Inventory-Short Form (BPI-SF), and a xerostomia assessment, all completed at each treatment cycle. Baseline PSMA PET parameters-including volume, SUVmean, SUVmax, and total lesion PSMA (TLP; calculated by multiplying SUVmean by volume) for whole-body disease, bone disease, and salivary glands-were quantified using TRAQinform IQ. Associations between these imaging metrics and clinical outcomes were assessed using univariate and multivariate models.

Results

Multivariate Cox regression analysis showed that higher baseline bone tumor SUVmean was significantly associated with delayed onset of grade 3 or 4 hematologic toxicity (hazard ratio [HR], 0.59; 95% CI, 0.36-0.98; P = 0.040), suggesting a protective effect. Conversely, higher bone TLP was associated with earlier onset of severe toxicity (HR, 1.31; 95% CI, 1.00-1.71; P = 0.049). Elevated whole-body SUVmean at baseline was predictive of delayed deterioration in both FACT-P total scores (HR, 0.59; 95% CI, 0.43-0.83; P = 0.002) and BPI-SF pain intensity (HR, 0.66; 95% CI, 0.46-0.93; P = 0.019). Additionally, higher salivary gland SUVmean, SUVmax, and TLP were significantly associated with increased xerostomia severity (P = 0.002, P = 0.006, and P = 0.015, respectively) in multivariate linear mixed-effects modeling.

Conclusion

In this retrospective analysis of patients with mCRPC treated with 177Lu-PSMA-617, baseline quantitative PSMA PET parameters were associated with both treatment-related toxicities and patient-reported outcomes. Validation in a larger, prospective, multicenter cohort is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DipeptidesHeterocyclic Compounds, 1-RingLutetiumQuality of LifeProstatic Neoplasms, Castration-ResistantGlutamate Carboxypeptidase IIPositron-Emission TomographyPainHumansMaleRetrospective StudiesAgedMiddle AgedAged, 80 and overAntigens, SurfaceRadioisotopesProstate-Specific Antigen

Stichwörter der Autor:innen

BPI-SFFACT-PPSMA RPTadverse hematologic eventsxerostomia

Substanzen

DipeptidesHeterocyclic Compounds, 1-RingLutetiumGlutamate Carboxypeptidase IIFOLH1 protein, humanLutetium-177PluvictoPSMA-617Antigens, SurfaceRadioisotopes

Autor:innen und Institutionen

  • Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California.
  • Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California; koichirokimura@mednet.ucla.edu.
  • Department of Medicine Statistics Core, David Geffen School of Medicine at UCLA, Los Angeles, California.
  • AIQ Solutions, Madison, Wisconsin.
  • Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.
  • Department of Medicine, VA Greater Los Angeles, Los Angeles, California; and.

Zitieren

APA

Murthy, V., Kimura, K., Theus, L., Nguyen, A., Grogan, T. R., Lokre, O., Perk, T., Rettig, M. B., Drakaki, A., Shen, J., Thin, P., Nguyen, K., Lira, S., Nabong, R. M., Gardner, L., Gonzalez, B. D., Gafita, A., Czernin, J., & Calais, J. (2026). Linking Baseline PSMA PETDerived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [ 177 Lu]Lu-PSMA-617: A Single-Center Retrospective Study. Journal of Nuclear Medicine, 67(2), 246-252. https://doi.org/10.2967/jnumed.125.270916

Vancouver

Murthy V, Kimura K, Theus L, Nguyen A, Grogan TR, Lokre O, et al. Linking Baseline PSMA PETDerived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [ 177 Lu]Lu-PSMA-617: A Single-Center Retrospective Study. Journal of Nuclear Medicine. 2026;67(2):246-252. doi:10.2967/jnumed.125.270916

BibTeX
@article{Murthy2026,
  author = {Murthy, Vishnu and Kimura, Koichiro and Theus, Lela and Nguyen, Andrew and Grogan, Tristan R and Lokre, Ojaswita and Perk, Timothy and Rettig, Matthew B and Drakaki, Alexandra and Shen, John and Thin, Pan and Nguyen, Kathleen and Lira, Stephanie and Nabong, Rejah Marie and Gardner, Linda and Gonzalez, Brian D and Gafita, Andrei and Czernin, Johannes and Calais, Jeremie},
  title = {Linking Baseline PSMA PETDerived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [ 177 Lu]Lu-PSMA-617: A Single-Center Retrospective Study},
  journal = {Journal of Nuclear Medicine},
  year = {2026},
  volume = {67},
  number = {2},
  pages = {246--252},
  doi = {10.2967/jnumed.125.270916}
}
Kostenlos starten →